Medtronic (MDT) Might Post "Better Than Expected Numbers," Says Jim Cramer

We recently published 10 Stocks Jim Cramer Talked About.  Medtronic plc (NYSE:MDT) is one of the stocks on Jim Cramer talked about.

Medtronic plc (NYSE:MDT) is a medical device company. Its shares are up by 12.9% over the past year. The past couple of months have seen several analysts discuss the firm. For instance, in December, Truist kept a Hold rating on Medtronic plc (NYSE:MDT)’s shares and reduced the price target to $107 from $110, as per The Fly. The financial firm pointed out that the company’s near-term valuation could experience macroeconomic headwinds. Truist’s action came after Stifel had also kept a Hold rating on Medtronic plc (NYSE:MDT)’s stock, along with a $105 share price target. Stifel’s commentary followed the Food and Drug Administration’s (FDA) approval of the medical device company’s HUGO platform, which it believes can lead to inroads into the hotly contested US surgical market. More recently, William Blair and Piper Sandler commented on the firm in January. The former upgraded the shares to Outperform from Market Perform, as it opined that the firm could deliver high single-digit earnings per share growth. The latter maintained a Neutral rating and a $105 share price target. With Medtronic plc (NYSE:MDT) expected to report numbers soon, Cramer briefly commented on the upcoming announcement:

“We have Medtronic, looks like better than expected numbers coming there.”

While we acknowledge the potential of MDT as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.